Resultats de la cerca - Eric Winquist

Refinar resultats
  1. 1
    Systemic therapy in the curative treatment of head and neck squamous cell cancer: A systematic review

    Systemic therapy in the curative treatment of head and neck squamous cell cancer: A systematic review per Eric Winquist, Chika Agbassi, Brandon M. Meyers, John Yoo, Kelvin Chan

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Epidermal Growth Factor Receptor Targeted Therapy in Stages III and IV Head and Neck Cancer

    Epidermal Growth Factor Receptor Targeted Therapy in Stages III and IV Head and Neck Cancer per C. Cripps, Eric Winquist, Michele deVries, Denise Stys‐Norman, Ralph Gilbert

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Plasma osteopontin

    Plasma osteopontin per Sébastien J. Hotte, Eric Winquist, Larry Stitt, Sylvia M. Wilson, Ann F. Chambers

    Publicat 2002
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy

    OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy per Wendy A. Teft, Stephen Welch, John Lenehan, Jeremy Parfitt, Yun‐Hee Choi, Eric Winquist, R B Kim

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer

    A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer per Scott A. Laurie, Lillian L. Siu, Eric Winquist, Andrew W. Maksymiuk, Erica Harnett, Wendy Walsh, Dongsheng Tu, Wendy R. Parulekar

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    An Evaluation Framework for Funding Drugs for Rare Diseases

    An Evaluation Framework for Funding Drugs for Rare Diseases per Eric Winquist, Chaim M. Bell, Joe T.R. Clarke, Gerald A. Evans, Janet Martin, Mona Sabharwal, Anita Gadhok, Helen Stevenson, Doug Coyle

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit

    Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit per Lori J. Wirth, Cosimo Durante, Duncan J. Topliss, Eric Winquist, Eyal Robenshtok, Hiroyuki Iwasaki, Markus Luster, Rossella Elisei, Sophie Leboulleux, Makoto Tahara

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

    Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion per Katherine S. Virgo, Ethan Basch, D.A. Loblaw, Thomas K. Oliver, R. Bryan Rumble, Michael A. Carducci, Luke T. Nordquist, Mary-Ellen Taplin, Eric Winquist, Eric A. Singer

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study

    Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Can... per Karin Oechsle, Friedemann Honecker, Tina Cheng, Frank Mayer, Piotr Czaykowski, Eric Winquist, Lori Wood, Martin Fenner, Stephanie Glaesener, J.T. Hartmann, K.N. Chi, Carsten Bokemeyer, Christian Kollmannsberger

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

    Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium... per Lillian L. Siu, Denis Soulières, Eric X. Chen, Gregory R. Pond, Soo Chin, P. Francis, Luc Harvey, M. Klein, Wenjiang Zhang, Janet Dancey, Elizabeth A. Eisenhauer, Eric Winquist

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

    A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and nec... per Antonio Jimeno, Keisuke Shirai, Minsig Choi, Janessa Laskin, Mark D. Kochenderfer, Alexander I. Spira, Vivian Jean M. Cline-Burkhardt, Eric Winquist, Diana F. Hausman, Luke Walker, Rachel Cohen

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study

    Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study per Sébastien J. Hotte, Eric Winquist, Elizabeth B. Lamont, Mary J. MacKenzie, Everett E. Vokes, Eric X. Chen, Shirley Brown, Gregory R. Pond, Anthony J. Murgo, Lillian L. Siu

    Publicat 2005
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

    Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer... per Fred Saad, Sébastien J. Hotte, Scott North, Bernhard J. Eigl, Kim Chi, Piotr Czaykowski, Lori Wood, Michaël Pollak, Scott Berry, Jean‐Baptiste Lattouf, Som D. Mukherjee, Martin Gleave, Eric Winquist

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management

    Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management per Özgür Mete, Andrée Boucher, Kasmintan A. Schrader, Omar Abdel‐Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole G. Chau, Shereen Ezzat

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma

    Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma per Christine Elser, Lillian L. Siu, Eric Winquist, Mark Agulnik, Gregory R. Pond, Soo Chin, P. Francis, R. Cheiken, James J. Elting, Angela McNabola, Dean Wilkie, Oana Petrenciuc, Eric X. Chen

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

    Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care per Fiona A. Miller, Robin Z. Hayeems, Jessica Bytautas, Philippe L. Bédard, Scott Ernst, Hal W. Hirte, Sébastien J. Hotte, Amit M. Oza, Albiruni Ryan Abdul Razak, Stephen Welch, Eric Winquist, Janet Dancey, Lillian L. Siu

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

    Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Car... per Joaquim Bellmunt, Christine Théodore, T. Demkov, B. K. Komyakov, Lisa Sengeløv, Gedske Daugaard, Armelle Caty, Joan Carles, Agnieszka Jagiełło-Gruszfeld, Oleg Karyakin, François-Michel Delgado, P Hurteloup, Eric Winquist, Nassim Morsli, Yacine Salhi, Stéphane Culine, Hans von der Maase

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

    Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer per Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, Anuradha Jayaram, Eric Winquist, Brigit McLaughlin, David Lu, Martin Fleisher, Sarah Orr, Lori E. Lowes, Amanda Anderson, Yipeng Wang, Ryan Dittamore, Alison L. Allan, Gerhardt Attard, Glenn Heller

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

    Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Sys... per Joaquim Bellmunt, Hans von der Maase, Graham M. Mead, Iwona Skoneczna, Maria De Santis, Gedske Daugaard, Andreas Boehle, Christine Chevreau, Luis Paz‐Ares, Leslie R. Laufman, Eric Winquist, Derek Raghavan, Sandrine Marréaud, Sandra Collette, Richard Sylvester, Ronald de Wit

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

    Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 rando... per Jan B. Vermorken, Jan Stöhlmacher-Williams, Ірина Давиденко, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Składowski, Makoto Tahara, Vasant R. Pai, Sandrine Faivre, C. Blajman, Arlene A. Forastiere, B. Stein, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: